FemTech Leader Willow ® Adds Diverse Set Of Investors In Extended Series C Round

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

Willow, the company forever changing the way moms pump with the world’s first all-in-one, in-bra wearable breast pump with full spill-proof mobility, today announced an additional $26.8 Million in funding through a Series C Extension round –  led by Endeavour Vision, alongside NEA (New Enterprise Associates), Pura Vida Investments, Purple Arch Ventures (a part of Alumni Ventures Group), Logos Capital, and Gaingels.

This extension brings Willow’s total Series C investment to $81.8 Million.  With the most innovative breast pump on the market, Willow will use its latest growth capital funding to invest in new products and further expand its reach.

“We are excited to lead Willow’s Series C extension to further support the accelerated growth ahead for the company,” said Rob Barmann, Partner at Endeavour Vision. “As the innovation leader in its category, we believe that Willow will continue to develop groundbreaking innovations that disrupt the FemTech and MedTech industries.”

Recognizing that the functionality of breast pumps hadn’t changed in decades, Willow became a pioneer in the FemTech category by reinventing the breast pump. Willow’s proprietary, patented technology offers 100% spill-proof mobility for pumping moms, giving them freedom, dignity, and enabling joy in an otherwise stress-inducing aspect of motherhood.

“I’m excited about the growth we’ve been able to accomplish, and impact we’ve had, in such a short time, towards our mission of bringing joy to motherhood,” said Willow CEO, Laura Chambers. “With this additional funding, we will expand our international presence, grow brand awareness, and accelerate our innovative R&D pipeline of products that solve real problems for moms.”

Willow launched as a direct-to-consumer brand, bringing life-changing technology to women experiencing new motherhood.  Willow has since expanded to reach moms through retail and insurance channels, and was the fastest-growing brand in 2020 in retail for breastfeeding systems, according to NPD Group.  Its innovative breast pump has impacted more than 130,000 moms and counting.

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.